| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 1996;28:652-655.)
© 1996 American Heart Association, Inc.
Articles |
Racial Differences in Plasma Endothelin-1 Concentrations in Individuals With Essential Hypertension
the Department of Internal Medicine, Mercer University School of Medicine–Medical Center of Central Georgia, Macon (S.E., D.C.P.), and Department of Biochemistry and Molecular Biology, University of Georgia, Athens (D.P., A.E.).
Correspondence to Dr Adviye Ergul, Department of Biochemistry and Molecular Biology, Life Sciences Building, University of Georgia, Athens, GA 30602-7229. E-mail aergul@uga.cc.uga.edu.
Hypertension is more prevalent in blacks than whites, and the reasons for this difference remain unclear. To test whether endothelin may play a role in these racial variations, we analyzed plasma samples from black and white women and men with high blood pressure by an enzyme-linked immunoassay specific for endothelin-1 (ET-1), a potent vasoconstrictor, and compared them with those obtained from similar subjects with normal blood pressure. Both female and male hypertensive blacks had elevated levels of immunoreactive ET-1 (11.3±1.0 and 12.3±1.3 nmol/L, respectively) compared with values in normotensive control blacks (1.5±0.2 and 1.4±0.2 nmol/L). Corresponding values in female and male hypertensive whites were 3.8±0.6 and 3.8±0.6 nmol/L, respectively, compared with respective values of 1.4±0.1 and 2.8±0.4 nmol/L in normotensive control whites. These results indicate that plasma concentrations of immunoreactive ET-1 levels differ significantly between black and white individuals with high blood pressure. This finding may be an important factor in the etiology of racial differences in the prevalence and severity of hypertension and deserves further study.
Key Words: endothelin • blood pressure • hypertension, essential • race • gender
This article has been cited by other articles:
 |
|
 |
|
  B. J Epstein Efficacy and Safety of Darusentan: A Novel Endothelin Receptor Antagonist Ann. Pharmacother., July 1, 2008; 42(7): 1060 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Portik-Dobos, A. K. Harris, W. Song, J. Hutchinson, M. H. Johnson, J. D. Imig, D. M. Pollock, and A. Ergul Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2006; 290(2): R435 - R441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ergul, J. S. Johansen, C. Stromhaug, A. K. Harris, J. Hutchinson, A. Tawfik, A. Rahimi, E. Rhim, B. Wells, R. W. Caldwell, et al. Vascular Dysfunction of Venous Bypass Conduits Is Mediated by Reactive Oxygen Species in Diabetes: Role of Endothelin-1 J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 70 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. del Villar, C. J. G. Alonso, C. A. Feldstein, L. A. Juncos, and J. C. Romero Role of Endothelin in the Pathogenesis of Hypertension Mayo Clin. Proc., January 1, 2005; 80(1): 84 - 96. [Abstract] [PDF]
|
|
|
|
 |
|
 M. D. Sosin, G. S. Bhatia, R. C. Davis, and G. Y.H. Lip Heart failure--the importance of ethnicity Eur J Heart Fail, December 1, 2004; 6(7): 831 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang and D. H. Wang Prevention of endothelin-1-induced increases in blood pressure: role of endogenous CGRP Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1868 - H1874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Campia, C. Cardillo, and J. A. Panza Ethnic Differences in the Vasoconstrictor Activity of Endogenous Endothelin-1 in Hypertensive Patients Circulation, June 29, 2004; 109(25): 3191 - 3195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Xiang, R. Denver, M. Bailey, and H. Krum Physiologic Determinants of Endothelin Concentrations in Human Saliva Clin. Chem., December 1, 2003; 49(12): 2012 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oparil, M. A. Zaman, and D. A. Calhoun Pathogenesis of Hypertension Ann Intern Med, November 4, 2003; 139(9): 761 - 776. [Full Text] [PDF]
|
|
|
|
|
|
A. Ergul, V. Portik-Dobos, A. D. Giulumian, M. M. Molero, and L. C. Fuchs Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H2225 - H2232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Jin, J. Nakura, Z. Wu, M. Yamamoto, M. Abe, Y. Tabara, Y. Yamamoto, M. Igase, K. Kohara, and T. Miki Association of Endothelin-1 Gene Variant With Hypertension Hypertension, January 1, 2003; 41(1): 163 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Treiber, G. K. Kapuku, H. Davis, J. S. Pollock, and D. M. Pollock Plasma Endothelin-1 Release During Acute Stress: Role of Ethnicity and Sex Psychosom Med, September 1, 2002; 64(5): 707 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Grubbs, M. P. Anstadt, and A. Ergul Saphenous Vein Endothelin System Expression and Activity in African American Patients Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1122 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Elijovich, C. L. Laffer, E. Amador, H. Gavras, M. R. Bresnahan, and E. L. Schiffrin Regulation of Plasma Endothelin by Salt in Salt-Sensitive Hypertension Circulation, January 16, 2001; 103(2): 263 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Luscher and M. Barton Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs Circulation, November 7, 2000; 102(19): 2434 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ruschitzka, U. Moehrlen, T. Quaschning, M. Lachat, G. Noll, S. Shaw, Z. Yang, D. Teupser, T. Subkowski, M. I. Turina, et al. Tissue Endothelin-Converting Enzyme Activity Correlates With Cardiovascular Risk Factors in Coronary Artery Disease Circulation, September 5, 2000; 102(10): 1086 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ergul Hypertension in Black Patients : An Emerging Role of the Endothelin System in Salt-Sensitive Hypertension Hypertension, July 1, 2000; 36(1): 62 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. BARTON, I. VOS, S. SHAW, P. BOER, L. V. D'USCIO, H.-J. GRÖNE, T. J. RABELINK, T. LATTMANN, P. MOREAU, and T. F. LÜSCHER Dysfunctional Renal Nitric Oxide Synthase as a Determinant of Salt-Sensitive Hypertension: Mechanisms of Renal Artery EndothelialDysfunction and Role of Endothelin for Vascular Hypertrophy andGlomerulosclerosis J. Am. Soc. Nephrol., May 1, 2000; 11(5): 835 - 845. [Abstract] [Full Text]
|
|
|
|
|
|
F. A. Treiber, R. W. Jackson, H. Davis, J. S. Pollock, G. Kapuku, G. A. Mensah, and D. M. Pollock Racial Differences in Endothelin-1 at Rest and in Response to Acute Stress in Adolescent Males Hypertension, March 1, 2000; 35(3): 722 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin Role of Endothelin-1 in Hypertension Hypertension, October 1, 1999; 34(4): 876 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tiret, O. Poirier, V. Hallet, T. A. McDonagh, C. Morrison, J. J. V. McMurray, H. J. Dargie, D. Arveiler, J.-B. Ruidavets, G. Luc, et al. The Lys198Asn Polymorphism in the Endothelin-1 Gene Is Associated With Blood Pressure in Overweight People Hypertension, May 1, 1999; 33(5): 1169 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J Rabelink, E. S.G Stroes, K.P. Bouter, and P. Morrison Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease? Cardiovasc Res, September 1, 1998; 39(3): 543 - 549. [Full Text] [PDF]
|
|
|
|
|
|
A. Ergul, K. Shoemaker, D. Puett, and R. L. Tackett Gender Differences in the Expression of Endothelin Receptors in Human Saphenous Veins In Vitro J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 511 - 517. [Abstract] [Full Text]
|
|
|
|
|
|
A. Huang and A. Koller Endothelin and Prostaglandin H2 Enhance Arteriolar Myogenic Tone in Hypertension Hypertension, November 1, 1997; 30(5): 1210 - 1215. [Abstract] [Full Text]
|
|
|
|
|
|
Correction Hypertension, March 1, 1997; 29(3): 912 - 912. [Full Text]
|
|
|
|
 |
|
 M. Suthanthiran, B. Li, J. O. Song, R. Ding, V. K. Sharma, J. E. Schwartz, and P. August Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage PNAS, March 28, 2000; 97(7): 3479 - 3484. [Abstract] [Full Text] [PDF]
|
|